Johnson & Johnson stock trades near record highs as 2026 revenue and EPS guidance rise

Johnson & Johnson (US4781601046) stock is trading close to record territory in late August 2026, with recent quotes around $271.00 and the shares having closed as high as $273.41 on August 19, 2026, while the company tightens its earnings guidance for 2026 and signals that annual revenue is on track to surpass $100 billion for the first time.

The latest market data as of August 23, 2026 show Johnson & Johnson changing hands at $271.00 with an intraday range between $267.00 and $272.66, leaving the stock fractionally below its recent record closing high and supporting a market capitalization reported at $651.38 billion. Per recent coverage, the shares have gained 29% in 2026 to date, underscoring how investors have repriced the company’s earnings trajectory as guidance improved.

According to recent analyst and market commentary, Johnson & Johnson has maintained its full-year 2026 adjusted EPS guidance in a range of $11.60 to $11.75 per share, while consensus forecasts cluster around $11.61, highlighting modest upside within the guidance band. The company also reiterated that revenue growth in its most recent quarter reached 6.6% year over year, with management raising reported-sales guidance to a midpoint of $101.1 billion for 2026 and lifting the midpoint of adjusted EPS guidance by $0.13 to $11.68.

Recent analysis of the company’s balance sheet notes that Johnson & Johnson ended fiscal second quarter 2026 with $21 billion of cash and marketable securities, giving it meaningful financial flexibility to keep investing in drug development, medical devices and shareholder returns while navigating patent expirations and ongoing legal settlements. The company’s dividend policy remains intact, with a declared quarterly payout of $1.34 per share that equates to $5.36 on an annual basis and a dividend yield of 2.0% at recent prices.

For income-focused investors, the upcoming dividend record and payment dates for this $1.34 quarterly distribution offer additional visibility. The dividend will be paid on September 8, 2026 to shareholders of record on August 25, 2026, with the ex-dividend date also set for August 25. At an annualized $5.36 per share, the payout represents a modest portion of the company’s guided EPS range for 2026, leaving room for both reinvestment and potential future increases depending on earnings momentum.

Guidance and earnings momentum

In its most recent quarterly update covering the second quarter of 2026, Johnson & Johnson reported that revenue grew 6.6% year over year, driven by gains in its Innovative Medicine segment and a normalization of demand across its product portfolio. Recent commentary emphasizes that Innovative Medicine sales reached $16.38 billion in the quarter, representing 7.8% growth, or 6.8% operationally when currency effects are excluded, even after accounting for headwinds from Stelara.

The company’s updated outlook now calls for reported 2026 sales to reach a midpoint of $101.1 billion, which would represent a milestone as Johnson & Johnson surpasses the $100 billion revenue mark for the first time in its history. At the same time, management increased the midpoint of its adjusted EPS guidance for 2026 by $0.13 to $11.68, while maintaining the broader guidance band at $11.60 to $11.75 per share. This combination of stronger top-line expectations and a higher earnings midpoint reflects confidence in both volume growth and pricing power across key therapies and devices.

Relative to the prior year, this guidance implies that Johnson & Johnson expects both revenue and adjusted earnings to grow in 2026, building on the 6.6% revenue increase already reported in the latest quarter. The fact that consensus forecasts sit at $11.61 per share while the company’s own guidance midpoint stands at $11.68 suggests a modest cushion between management’s expectations and the average analyst model, which can help support the stock if execution remains on track.

Recent discussions of the company’s performance also highlight that Stelara, a major immunology drug approaching a patent cliff, reduced the Innovative Medicine segment’s operational growth by 760 basis points in the quarter. Even after this drag, segment sales still grew at a mid-single-digit operational rate, indicating that newer therapies and indications are filling part of the gap and providing a runway for continued revenue expansion once biosimilar competition arrives.

Valuation, consensus and stock performance

On the valuation side, Johnson & Johnson’s shares opened at $270.69 in recent trading sessions, aligning closely with the latest quote of $271.00 and leaving the stock near its 52-week high after a strong run in 2026. The stock’s 50-day moving average price of $255.08 and 200-day moving average of $242.72 highlight how the rally has lifted the shares well above their medium- and longer-term trend levels, reflecting improved sentiment as legal overhangs ease and guidance firms up.

Market data and analyst compilations show that Johnson & Johnson currently carries a consensus rating characterized as a Moderate Buy, with an average 12-month price target of $268.22. With the shares trading around $271.00, the stock now sits slightly above this average target level, underscoring that much of the near-term optimism around guidance and legal risk reduction has been priced in. Nevertheless, the consensus view still points to relatively stable to slightly positive expectations for the company’s earnings and cash flow profile.

Recent reports also describe that the stock has climbed 29% in 2026 so far, outperforming many broader market benchmarks and underlining how quickly sentiment has shifted in the company’s favor. This move has been supported by a combination of better-than-expected quarterly results, incrementally higher guidance and progress in resolving long-running litigation, including a $5.5 billion talc settlement that reduces uncertainty around future payouts.

For investors evaluating valuation versus growth, the guidance midpoint of $11.68 in adjusted EPS provides a useful anchor against which to assess the current price level around $271.00. On that basis, the shares trade at a mid-20s multiple of 2026 earnings, a level that reflects Johnson & Johnson’s diversified portfolio, strong balance sheet and reputation for steady dividend growth but also embeds expectations that management will execute on its innovation and cost-control plans.

Legal settlements and balance sheet strength

Legal risk has long been a key consideration in assessing Johnson & Johnson, particularly regarding talc-related liabilities. Recent reporting describes a $5.5 billion talc settlement agreement that, while significant, is now framed within the context of the company’s large cash position and robust operating cash flow. Ending the fiscal second quarter of 2026 with $21 billion in cash and marketable securities, Johnson & Johnson has ample resources to fund settlements while continuing to invest in research and development, acquisitions and shareholder returns.

The reduced legal uncertainty contributes to the company’s willingness to reaffirm and slightly raise guidance, as management gains better visibility into the timing and magnitude of payouts. It also supports the credit profile, which remains strong thanks to the combination of cash, conservative leverage and diversified earnings streams across pharmaceuticals and medical devices.

Investors often compare Johnson & Johnson’s positioning with that of other large pharmaceutical peers as they approach their respective patent cliffs. Recent comparative analysis highlights that the company’s mix of innovative therapies, pipeline assets and medical technology platforms may leave it better prepared for this transition than some rivals, particularly given its focus on high-value therapeutic areas and minimally invasive procedural technologies.

Product spotlight: MONARCH QUEST 3 robotic bronchoscopy

Beyond traditional pharmaceuticals, Johnson & Johnson is building a growing presence in medical technology, including robotic-assisted procedures. Recent news has highlighted that the company received 510(k) clearance from the U.S. Food and Drug Administration for an update to its MONARCH QUEST 3 robotic bronchoscopy platform. This system is designed to help physicians navigate the lungs and collect tissue samples from small, hard-to-reach nodules, supporting earlier and more accurate diagnosis of lung conditions.

The MONARCH QUEST 3 system aims to integrate advanced imaging, flexible navigation and precise instrument control in order to enhance both diagnostic yield and procedural safety. By combining robotics with real-time imaging, the platform seeks to provide pulmonologists and thoracic surgeons with better visualization and control when accessing peripheral lung lesions that might otherwise be difficult to biopsy using conventional techniques.

As Johnson & Johnson pushes further into digitally enabled and robotic medical technologies, systems like MONARCH QUEST 3 could become important contributors to the company’s long-term growth story. They also create potential synergies with the company’s existing portfolio of interventional tools and devices, reinforcing its strategic emphasis on minimally invasive procedures and earlier disease detection alongside its pharmaceutical offerings.

Stock level and closing context

In the latest available trading data as of August 23, 2026, Johnson & Johnson stock is quoted at $271.00 on the New York Stock Exchange, with an intraday range between $267.00 and $272.66 and a reported market capitalization of $651.38 billion. The shares remain slightly below their August 19, 2026 record closing high of $273.41, reflecting a brief consolidation after a strong 29% advance since the start of the year.

With revenue growth of 6.6% in the most recent quarter, updated 2026 sales guidance centered on $101.1 billion, adjusted EPS guidance nudged to a midpoint of $11.68 and a $5.36 annualized dividend yielding 2.0%, Johnson & Johnson offers investors a combination of growth, income and balance sheet resilience that continues to underpin interest in the stock at current levels.

Fact box

Company: Johnson & Johnson

ISIN: US4781601046

Ticker: JNJ

Exchange: New York Stock Exchange (NYSE)

Price (as of August 23, 2026, 4:00 p.m. ET): $271.00 USD

Market cap: $651.38 billion (as of August 23, 2026)

Sector / Industry: Health Care / Pharmaceuticals and Medical Devices

Index membership: S&P 500